Bicycle Therapeutics Plc (NASDAQ:BCYC) reported Q2 2025 GAAP revenue of $2.9 million, significantly below the $9.43 million analyst estimate, while net loss per share widened to $(1.14), surpassing the $(0.95) forecast. Despite increased clinical investment and operational spending aimed at advancing its pipeline of precision-guided therapeutics using its proprietary Bicycle molecule platform, the company emphasized the need for operational discipline and clear milestones ahead.
Want More Context? 🔎
Alpha Metallurgical Cuts Costs in Q2
Alpha Metallurgical Resources (NYSE:AMR) reported second quarter 2025 results with an adjusted EBITDA of $46.1 million from 3.9 million tons shipped, achieving a $10 per ton reduction in coal sales costs. The company improved liquidity to $557 million, restarted its share buyback program, and lowered its cost guidance, highlighting operational efficiency amidst declining met coal prices. Want More Context? 🔎
Read more